Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02573363 · ClinicalTrials.gov registry record · Phase 1
Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02573363 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 25 participants.
The verdict
NCT02573363, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and the best dose of selinexor when give together with standard chemotherapy, high dose cytarabine and mitoxantrone hydrochloride, in treating patients with acute myeloid leukemia. Selinexor may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and mitoxantrone hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving selinexor together with standard chemotherapy may be a better treatment for patients with acute myeloid leukemia.
Interventions
- DRUG Selinexor
- DRUG Cytarabine
- DRUG Mitoxantrone Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-10-07 |
| Est. Completion | 2019-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02573363
The ClinicalTrials.gov registry entry for NCT02573363 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Selinexor is the first listed.
NCT02573363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02573363 about?
NCT02573363 is a clinical study titled "Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia". This phase I trial studies the side effects and the best dose of selinexor when give together with standard chemotherapy, high dose cytarabine and mitoxantrone hydrochloride, in treating patients with acute myeloid leukemia. Selinexor may stop the growth of cancer cells by blocking some of the enzym...
What is the current status of trial NCT02573363?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2015-10-07. Estimated completion is 2019-05-03.
What interventions are being tested in trial NCT02573363?
The interventions under investigation include: Selinexor (DRUG), Cytarabine (DRUG), Mitoxantrone Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02573363?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.